

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MacDonald Brian Richard</u>			2. Issuer Name and Ticker or Trading Symbol <u>Disc Medicine, Inc. [ IRON ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Innovation Officer</u>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>06/28/2023</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) WATERTOWN MA 02472			Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/28/2023		S <sup>(1)</sup>		2,247	D	\$49.243 <sup>(2)</sup>	25,153	D	
Common Stock	06/28/2023		S <sup>(1)</sup>		1,900	D	\$50.3844 <sup>(3)</sup>	23,253	D	
Common Stock	06/28/2023		S <sup>(1)</sup>		953	D	\$50.8032 <sup>(4)</sup>	22,300	D	
Common Stock	06/29/2023		S <sup>(1)</sup>		736	D	\$44.3698 <sup>(5)</sup>	21,564	D	
Common Stock	06/29/2023		S <sup>(1)</sup>		2,230	D	\$45.4946 <sup>(6)</sup>	19,334	D	
Common Stock	06/29/2023		S <sup>(1)</sup>		1,934	D	\$46.511 <sup>(7)</sup>	17,400	D	
Common Stock	06/29/2023		S <sup>(1)</sup>		200	D	\$47.24 <sup>(8)</sup>	17,200	D	
Common Stock	06/30/2023		S <sup>(1)</sup>		2,923	D	\$44.8518 <sup>(9)</sup>	14,277	D	
Common Stock	06/30/2023		S <sup>(1)</sup>		1,401	D	\$45.4506 <sup>(10)</sup>	12,876	D	
Common Stock	06/30/2023		S <sup>(1)</sup>		600	A	\$46.7633 <sup>(11)</sup>	12,276	D	
Common Stock								1,096	I	Held by Son <sup>(12)</sup>
Common Stock								1,096	I	Held by Son <sup>(12)</sup>
Common Stock								1,096	I	Held by Son <sup>(12)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Explanation of Responses:

- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$48.61 to \$49.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (11) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$49.61 to \$50.59, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$50.62 to \$51.235, inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$44.03 to \$44.87, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$45.03 to \$45.94, inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$46.04 to \$46.96, inclusive.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$47.23 to \$47.25, inclusive.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$44.31 to \$45.29, inclusive.
10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$45.31 to \$45.58, inclusive.
11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$46.56 to \$47.00, inclusive.
12. The Reporting Person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

By: /s/ Rahul Khara, as                      06/30/2023  
Attorney-in-Fact

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**